Technology | Intensity Modulated Radiation Therapy (IMRT) | July 05, 2017

Varian Receives FDA 510k Clearance for Halcyon Treatment System

New intensity modulated radiotherapy system now has 510(k) clearance and CE mark

Varian Receives FDA 510k Clearance for Halcyon Treatment System

July 5, 2017 — Varian Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Halcyon system, its new device for cancer treatment. Halcyon simplifies and enhances virtually every aspect of image-guided volumetric intensity modulated radiotherapy (IMRT), according to the company.

Halcyon is an advanced system that is more comfortable for the patient while delivering ease of use for healthcare providers, accelerated installation timeframes, expedited commissioning, simplified training and automated treatment. With its streamlined workflow, the system only requires nine steps from the start to the end of treatment compared to up to more than 30 steps with older technologies. Halcyon is well suited to handle the majority of cancer patients, according to Varian, offering advanced treatments for prostate, breast, head & neck, and many other forms of cancer. 

Halcyon features large touchscreens on both sides of the machine to assist in easy patient set-up. For increased patient comfort, Halcyon is up to two times quieter than other systems, has a low couch height for easy patient access and soft indirect ambient lighting in the gantry opening. To create a closer connection between patient and therapist during Halcyon treatment, the system includes an integrated couch-mounted camera for the therapist to watch over the patient during treatment, and an integrated noise-cancelling sound system that makes it easy for patients to converse with the therapists.

With 510(k) clearance, Varian can begin selling the Halcyon system in the United States. The system requires Eclipse 15.1.1 treatment planning software, which is currently 510(k) pending. 

For more information: www.varian.com/halcyon

Related Content

Videos | Radiation Therapy | February 15, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
New Targeted Therapy for Recurrent Brain Tumors Implanted for First Time
News | Radiation Therapy | February 15, 2019
University of Minnesota Health (M Health) is the first in the United States to begin offering GammaTile Therapy, a new...
Canon Adds Radiation Therapy Package to Aquilion Prime, Lightning CT Systems
News | Computed Tomography (CT) | February 11, 2019
In the patient-centric world of radiation oncology, it is critical that computed tomography (CT) simulation is...
Elekta Unity MR-Linac Earns FDA Clearance
Technology | Image Guided Radiation Therapy (IGRT) | February 07, 2019
The Elekta Unity magnetic resonance radiation therapy (MR/RT) system recently received 510(k) premarket notification...
University of Oklahoma Cancer Center Begins First Proton Therapy Treatments
News | Proton Therapy | February 01, 2019
Home to the largest and most comprehensive radiation therapy program in Oklahoma, the Stephenson Cancer Center at OU (...
Stereotactic Radiotherapy Improves Long-Term Survival in Stage-IV Cancers
News | Stereotactic Body Radiation Therapy (SBRT) | January 31, 2019
The first report from a phase II, multi-center clinical trial indicates stereotactic radiation can extend long-term...
Philips Collaborates With MIM Software on Radiation Therapy Treatment Planning
News | Treatment Planning | January 31, 2019
January 31, 2019 — Philips announced a collaboration with imaging solutions provider MIM Software Inc.
Laurent Levy, CEO of Nanobiotix, explains the use of his company’s nanoparticles to enhance the radiation sensitivity of tumor tissue to improve patient outcomes

Laurent Levy, CEO of Nanobiotix, explains the use of his company’s nanoparticles to enhance the radiation sensitivity of tumor tissue to improve patient outcomes. The metallic-based nanoparticles show up on CT scans so it can be used as a permanent fiduciary marker to track tumor response. The images show the initial tumor and enhancement areas due to the nanoparticles and the resulting outcomes following treatment. Photo by Dave Fornell

Feature | Radiation Oncology | January 30, 2019 | By Dave Fornell
Artificial intelligence (AI) has been the hot topic discussed at all trade shows, and the...
Videos | Lung Cancer | January 29, 2019
Gregory Videtic, M.D., staff physician in radiation oncology at the Cleveland Clinic, and David Johnstone, M.D., prof
Southern Asia's First Proton Therapy Center Begins Treatments
News | Proton Therapy | January 28, 2019
IBA (Ion Beam Applications SA) announced the opening of the Apollo Proton Cancer Centre in Chennai, India, and the...